Table 1.
Patient characteristics at baselinea
| Characteristic | N = 15 |
|---|---|
| Sex: n (%) | |
| Female | 14 (93.3) |
| Male | 1 (6.7) |
| Age: median (range) | |
| Age at baseline (years) | 69 (30–76) |
| ECOG performance status: n (%) | |
| ECOG 0 | 9 (60) |
| ECOG 1 | 6 (40) |
| Presence of neurological symptoms at baseline: n (%) | |
| Yes | 6 (40) |
| No | 9 (60) |
| Disease subtype: n (%) | |
| HER2-positive/luminal B | 12(80) |
| HER2-positive/nonluminal | 3 (20) |
| Disease stage at primary diagnosis: n (%) | |
| Stage IV | 10 (66.7) |
| Stage I–III | 5 (33.3) |
| Brain metastasis-free survival (BMFS): median (range) | |
| BMFS from diagnosis of metastatic disease (months) | 17 (0-48) |
| Brain-only disease: n (%) | |
| Yes | 2 (13.3) |
| No | 13 (86.7) |
| Visceral metastases: n (%) | |
| Yes | 12 (80) |
| No | 3 (20) |
| GPA indexb at baseline: n (%) | |
| GPA 2.5 | 3 (20) |
| GPA 3.0 | 11 (73.3) |
| GPA 3.5 | 1 (6.7) |
| Previous HER2-directed therapy: n (%) | |
| Trastuzumab + pertuzumab | 15 (100) |
| T-DM1 | 9 (60) |
| Lapatinib | 4 (26.7) |
| Other | 1 (6.7) |
| Status of brain metastases; n (%) | |
| Untreated | 6 (40) |
| Primary brain metastases after previous local therapy | 9 (60) |
| Type of previous local therapy for brain metastases: n (%) | |
| WBRT | 3 (20) |
| WBRT + SRT/SRS and/or neurosurgery | 3 (20) |
| SRT/SRS | 3 (20) |
| Time from last previous local intervention to inclusion: median (range) | |
| Time from last local treatment (months) | 13 (5–65) |
| Previous lines of treatment for metastatic breast cancer: median (range) | |
| Number of previous lines of treatment before trastuzumab deruxtecan | 2 (1–5) |
aN, Number of patients in the ITT population; n, number of patients.
bGPA, Graded Prognostic Assessment, breast cancer specific. Sparduto P. W. et al. Beyond an updated Graded Prognostic Assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int. J. Radiat. Oncol. Biol. Phys. 107, 334–343 (2020).